A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma

This study is evaluating a special type of CT scan called spectral CT to see how accurately it can assess whether a liver cancer treatment called TACE (a procedure that delivers chemotherapy directly to the tumor via a blood vessel) has worked. Researchers want to see if spectral CT is better than standard CT scans at detecting whether any cancer remains after treatment. **You may be eligible if:** - You are aged 18 to 75 and have been diagnosed with hepatocellular carcinoma (primary liver cancer) - Your liver cancer is at an early or intermediate stage (BCLC stage A or B) - You have undergone or are planning TACE treatment - You are scheduled for either follow-up imaging, surgery, or another procedure after TACE - You are able and willing to provide informed consent **You may NOT be eligible if:** - You have a known allergy or contraindication to CT contrast dye - You have cancer outside the liver - You have had radiation therapy previously - Your imaging quality is too poor to analyze, or your clinical records are incomplete Talk to your doctor to see if this trial is right for you.